{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:50:26Z","timestamp":1768819826901,"version":"3.49.0"},"reference-count":29,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2022]]},"DOI":"10.1620\/tjem.2022.j084","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T22:22:28Z","timestamp":1665699748000},"page":"277-285","source":"Crossref","is-referenced-by-count":5,"title":["Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir"],"prefix":"10.1620","volume":"258","author":[{"given":"Kosuke","family":"Sato","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Ishinomaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tohoku Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Iwaki City Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yamagata City Hospital Saiseikan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Sato","sequence":"additional","affiliation":[{"name":"LC Clinic Sendai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, South Miyagi Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Iwata","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tsuruoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Onuki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Sawahashi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Niitsuma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Agarwal, K., Brunetto, M., Seto, W.K., Lim, Y.S., Fung, S., Marcellin, P., Ahn, S.H., Izumi, N., Chuang, W.L., Bae, H., Sharma, M., Janssen, H.L.A., Pan, C.Q., \u00c7elen, M.K., Furusyo, N.,  et al. (2018)  96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.  <i>J. Hepatol<\/i>., 68, 672-681.","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Buti, M., Gane, E., Seto, W.K., Chan, H.L., Chuang, W.L., Stepanova, T., Hui, A.J., Lim, Y.S., Mehta, R., Janssen, H.L., Acharya, S.K., Flaherty, J.F., Massetto, B., Cathcart, A.L., Kim, K.,  et al. (2016)  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.  <i>Lancet Gastroenterol. Hepatol<\/i>., 1, 196-206.","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chan, H.L., Fung, S., Seto, W.K., Chuang, W.L., Chen, C.Y., Kim, H.J., Hui, A.J., Janssen, H.L., Chowdhury, A., Tsang, T.Y., Mehta, R., Gane, E., Flaherty, J.F., Massetto, B., Gaggar, A.,  et al. (2016)  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.  <i>Lancet Gastroenterol. Hepatol<\/i>., 1, 185-195.","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"4","unstructured":"European Association for the Study of the Liver (2017)  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.  <i>J. Hepatol<\/i>., 67, 370-398."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Inoue, J., Akahane, T., Kobayashi, T., Obara, N., Umetsu, T., Kakazu, E., Ninomiya, M., Iwata, T., Sano, A., Tsuruoka, M., Sato, K. &amp; Masamune, A. (2021)  Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: a pilot randomized controlled study.  <i>Biomed. Rep<\/i>., 14, 20.","DOI":"10.3892\/br.2020.1396"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Inoue, J., Akahane, T., Nakayama, H., Kimura, O., Kobayashi, T., Kisara, N., Sato, T., Morosawa, T., Izuma, M., Kakazu, E., Ninomiya, M., Iwata, T., Takai, S., Nakamura, T., Sano, A.,  et al. (2019)  Comparison of hepatitis\u00a0B virus genotypes\u00a0B and C among chronically hepatitis\u00a0B virus-infected patients who received nucleos(t)ide analogs: a multicenter retrospective study.  <i>Hepatol. Res<\/i>., 49, 1263-1274.","DOI":"10.1111\/hepr.13398"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Inoue, J., Kobayashi, T., Akahane, T., Kimura, O., Sato, K., Ninomiya, M., Iwata, T., Takai, S., Kisara, N., Sato, T., Nagasaki, F., Miura, M., Nakamura, T., Umetsu, T., Sano, A.,  et al. (2022)  Non-achievement of alanine aminotransferase normalization associated with the risk of hepatocellular carcinoma during nucleos(t)ide analogue therapies: a multicenter retrospective study.  <i>J. Clin. Med<\/i>., 11, 2354.","DOI":"10.3390\/jcm11092354"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Jung, H.J., Ho, M.J., Ahn, S., Han, Y.T. &amp; Kang, M.J. (2018)  Synthesis and physicochemical evaluation of entecavir-fatty acid conjugates in reducing food effect on intestinal absorption.  <i>Molecules<\/i>, 23, 731.","DOI":"10.3390\/molecules23040731"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kaneko, S., Kurosaki, M., Joko, K., Marusawa, H., Kondo, M., Kojima, Y., Uchida, Y., Kimura, H., Tsuji, K., Yagisawa, H., Kusakabe, A., Kobashi, H., Akahane, T., Tamaki, N., Kirino, S.,  et al. (2020)  Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.  <i>Sci. Rep<\/i>., 10, 13021.","DOI":"10.1038\/s41598-020-69522-w"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Sinn, D.H., Kang, W., Gwak, G.Y., Paik, Y.H., Choi, M.S., Lee, J.H., Koh, K.C. &amp; Paik, S.W. (2017)  Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.  <i>Hepatology<\/i>, 66, 335-343.","DOI":"10.1002\/hep.28916"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Koike, K., Suyama, K., Ito, H., Itoh, H. &amp; Sugiura, W. (2018)  Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients.  <i>Hepatol. Res<\/i>., 48, 59-68.","DOI":"10.1111\/hepr.12902"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Li, Z.B., Li, L., Niu, X.X., Chen, S.H., Fu, Y.M., Wang, C.Y., Liu, Y., Shao, Q., Chen, G. &amp; Ji, D. (2021)  Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.  <i>Liver Int<\/i>., 41, 1254-1264.","DOI":"10.1111\/liv.14786"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., Tanwandee, T., Tao, Q.M., Shue, K., Keene, O.N., Dixon, J.S.,  Gray, D.F. &amp; Sabbat, J.; Cirrhosis Asian Lamivudine Multicentre Study Group (2004)  Lamivudine for patients with chronic hepatitis B and advanced liver disease.  <i>N. Engl. J. Med<\/i>., 351, 1521-1531.","DOI":"10.1056\/NEJMoa033364"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Marcellin, P., Chang, T.T., Lim, S.G., Tong, M.J., Sievert, W., Shiffman, M.L., Jeffers, L., Goodman, Z., Wulfsohn, M.S., Xiong, S.,  Fry, J. &amp; Brosgart, C.L.; Adefovir Dipivoxil 437 Study Group (2003)  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.  <i>N. Engl. J. Med<\/i>., 348, 808-816.","DOI":"10.1056\/NEJMoa020681"},{"key":"15","doi-asserted-by":"crossref","unstructured":"McPherson, S., Stewart, S.F., Henderson, E., Burt, A.D. &amp; Day, C.P. (2010)  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.  <i>Gut<\/i>, 59, 1265-1269.","DOI":"10.1136\/gut.2010.216077"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Murata, K., Tsukuda, S., Suizu, F., Kimura, A., Sugiyama, M., Watashi, K., Noguchi, M. &amp; Mizokami, M. (2020)  Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection.  <i>Hepatology<\/i>, 71, 1533-1545.","DOI":"10.1002\/hep.30956"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Nguyen, M.H., Atsukawa, M., Ishikawa, T., Yasuda, S., Yokohama, K., Trinh, H.N., Arai, T., Fukunishi, S., Ogawa, E., Hsu, Y.C., Maeda, M., Dang, H., Tseng, C.H., Takahashi, H., Jun, D.W.,  et al. (2021)  Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir.  <i>Am. J. Gastroenterol<\/i>., 116, 1264-1273.","DOI":"10.14309\/ajg.0000000000001157"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Ogawa, E., Nakamuta, M., Koyanagi, T., Ooho, A., Furusyo, N., Kajiwara, E., Dohmen, K., Kawano, A., Satoh, T., Takahashi, K., Azuma, K., Yamashita, N., Yamashita, N., Sugimoto, R., Amagase, H.,  et al. (2022)  Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multicentre cohort study.  <i>Aliment. Pharmacol. Ther<\/i>., 56, 713-722.","DOI":"10.1111\/apt.17107"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Papatheodoridis, G.V., Chan, H.L., Hansen, B.E., Janssen, H.L. &amp; Lampertico, P. (2015)  Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.  <i>J. Hepatol<\/i>., 62, 956-967.","DOI":"10.1016\/j.jhep.2015.01.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L., Chen, C.J., Chen, D.S., Chen, H.L., Chen, P.J., Chien, R.N., Dokmeci, A.K., Gane, E., Hou, J.L., Jafri, W., Jia, J.,  et al. (2016)  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.  <i>Hepatol. Int<\/i>., 10, 1-98.","DOI":"10.1007\/s12072-015-9675-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Sato, K., Inoue, J., Akahane, T., Kobayashi, T., Sato, S., Kisara, N., Ninomiya, M., Iwata, T., Sano, A., Tsuruoka, M., Onuki, M. &amp; Masamune, A. (2022)  Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: a prospective, multicenter, randomized controlled study.  <i>Medicine (Baltimore)<\/i>, 101, e30630.","DOI":"10.1097\/MD.0000000000030630"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Singal, A.K., Salameh, H., Kuo, Y.F. &amp; Fontana, R.J. (2013)  Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.  <i>Aliment. Pharmacol. Ther<\/i>., 38, 98-106.","DOI":"10.1111\/apt.12344"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Sinn, D.H., Lee, J., Goo, J., Kim, K., Gwak, G.Y., Paik, Y.H., Choi, M.S., Lee, J.H., Koh, K.C., Yoo, B.C. &amp; Paik, S.W. (2015)  Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.  <i>Hepatology<\/i>, 62, 694-701.","DOI":"10.1002\/hep.27889"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Sterling, R.K., Lissen, E., Clumeck, N., Sola, R., Correa, M.C., Montaner, J., Sulkowski M.S Torriani, F.J., Dieterich, D.T., Thomas, D.L.,  Messinger, D. &amp; Nelson, M.; APRICOT Clinical Investigators (2006)  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.  <i>Hepatology<\/i>, 43, 1317-1325.","DOI":"10.1002\/hep.21178"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Sun, Y., Wu, X., Zhou, J., Meng, T., Wang, B., Chen, S., Liu, H., Wang, T., Zhao, X., Wu, S., Kong, Y., Ou, X., Wee, A., Theise, N.D., Qiu, C.,  et al. (2020)  Persistent low level of hepatitis B virus promotes fibrosis progression during therapy.  <i>Clin. Gastroenterol. Hepatol<\/i>., 18, 2582-2591.e2586.","DOI":"10.1016\/j.cgh.2020.03.001"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K.M., Hwang, J.P., Jonas, M.M., Brown, R.S. Jr., Bzowej, N.H. &amp; Wong, J.B. (2018)  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.  <i>Hepatology<\/i>, 67, 1560-1599.","DOI":"10.1002\/hep.29800"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Uchida, Y., Nakao, M., Tsuji, S., Uemura, H., Kouyama, J.I., Naiki, K., Motoya, D., Sugawara, K., Nakayama, N., Imai, Y., Tomiya, T. &amp; Mochida, S. (2020)  Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.  <i>J. Med. Virol<\/i>., 92, 329-338.","DOI":"10.1002\/jmv.25644"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Uchida, Y., Nakao, M., Yamada, S., Tsuji, S., Uemura, H., Kouyama, J.I., Naiki, K., Sugawara, K., Nakayama, N., Imai, Y., Tomiya, T. &amp; Mochida, S. (2022)  Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: a 144-week outcome study after switching of the nucleos(t)ide analog.  <i>PLoS One<\/i>, 17, e0262764.","DOI":"10.1371\/journal.pone.0262764"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Yamashige, D., Hosaka, T., Suzuki, F., Fujiyama, S., Kawamura, Y., Sezaki, H., Akuta, N., Kobayashi, M., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M. &amp; Kumada, H. (2021)  Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.  <i>J. Gastroenterol<\/i>., 56, 1008-1021.","DOI":"10.1007\/s00535-021-01826-8"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/4\/258_2022.J084\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T04:57:12Z","timestamp":1668229032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/4\/258_2022.J084\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2022.j084","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"2022.J084"}}